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The benefits—and limits— 
of PPIs with warfarin regimens 
Patients on warfarin + antiplatelet/NSAID regimens are 
likely to benefit from the gastroprotective effect of PPIs. 
For patients taking warfarin alone, it’s a different story. 
PRACTICE CHANGER
Prescribe a proton pump inhibitor for pa-
tients taking dual antiplatelet/antithrombotic 
therapy to reduce the risk of upper gastroin-
testinal bleeding.
STRENGTH OF RECOMMENDATION
B: Based on a cohort study
Ray WA, Chung CP, Murray KT, et al. Association of proton pump in-
hibitors with reduced risk of warfarin-related serious upper gastroin-
testinal bleeding. Gastroenterology. 2016;151:1105-1112.1 
ILLUSTRATIVE CASE
A 60-year-old man establishes care with you. 
He has well-controlled osteoarthritis (as long 
as he takes his low-dose daily aspirin) and 
chronic atrial fibrillation, for which he takes 
warfarin. His international normalized ratio 
(INR) is consistently within the recommended 
target range of 2 to 3. He feels well and has 
never had gastroesophageal reflux disease 
(GERD) or a gastrointestinal (GI) bleed. Should 
you recommend a proton pump inhibitor (PPI) 
to decrease the likelihood of a future upper 
GI bleed?
Anticoagulation therapy creates a di-lemma—the need to balance the benefits of preventing embolization 
with the risks of serious bleeding. Concurrent 
use of nonsteroidal anti-inflammatory drugs 
(NSAIDs), aspirin, and other antiplatelet 
agents further increases the risk of the latter.2
Physicians have long used PPIs to treat 
upper GI bleeds. They prevent acid secretion 
and are the most efficacious drugs for heal-
ing peptic ulcers.3,4 However, while previous 
case-control studies show that PPIs reduce 
the risk of upper GI bleeds in patients tak-
ing antiplatelet agents or NSAIDs, they do 
not show a statistically significant benefit for 
patients taking warfarin.5,6 Further reflecting 
the confusion and uncertainty surrounding 
this issue is that while one expert consensus 
report recommends that patients taking dual 
warfarin and antiplatelet agent/NSAID ther-
apy take a PPI to decrease the risk of upper 
GI bleeding,2 other guidelines regarding anti-
coagulant therapy do not address this clinical 
question.2,7,8
STUDY SUMMARY
Study lends support to PPI use  
in a high-risk group 
This retrospective cohort study sought to 
answer the question: “Does PPI co-therapy 
decrease the rate of serious upper GI bleeds 
in patients taking warfarin?” Researchers ex-
amined rates of hospitalization for upper GI 
bleeding for Medicare and Medicaid patients 
taking warfarin with and without PPI co- 
therapy (tracked via prescription fill dates). 
They also evaluated concomitant use of 
NSAIDs and antiplatelet agents. 
The authors excluded patients with a 
recent history of a severe bleed or certain ill-
nesses that would predispose a patient to GI 
bleeding (such as esophageal varices). Pa-
tients with risk factors for an upper GI bleed 
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(such as abdominal pain, peptic ulcer dis-
ease, anemia, etc.) were more likely to be tak-
ing PPI co-therapy. Researchers analyzed the 
effect of PPI co-therapy in patients with and 
without these additional risk factors. 
❚ Results. The study followed over 75,000 
person-years of active warfarin therapy (more 
than 52,000 person-years in the Medicaid co-
hort and more than 23,000 person-years in the 
Medicare cohort). Hospitalizations due to up-
per GI bleeding occurred at a rate of 127/10,000 
person-years (incidence was similar in both 
the Medicaid and Medicare groups). 
Looking at all patients taking warfarin 
(regardless of whether or not they were also 
taking an NSAID or antiplatelet agent), PPI 
co-therapy reduced the risk of hospitaliza-
tion for upper GI bleeding by 24% (adjusted 
hazard ratio [HR]=0.76; 95% confidence in-
terval [CI], 0.63 to 0.91), which translates into 
29 fewer hospitalizations per 10,000 person-
years. The number needed to treat (NNT) 
was 345 person-years, meaning 345 patients 
taking warfarin would have to take a PPI for 
one year to prevent one hospitalization for an 
upper GI bleed. As one might expect, PPI co-
therapy did not significantly reduce the risk 
of lower GI, other GI, or non-GI bleeding.
In patients taking both warfarin and 
concurrent antiplatelet agents or NSAIDs, 
PPI co-therapy reduced the risk of hospital-
ization for upper GI bleeding by about half 
(HR=0.55; 95% CI, 0.39-0.77). Hospitaliza-
tions decreased by 128/10,000 person-years 
(95% CI, -66 to -173), yielding an NNT of 
78 person-years. For patients taking warfarin 
but not antiplatelet agents or NSAIDs, PPI 
co-therapy did not significantly decrease the 
risk of hospitalization for upper GI bleeding 
(HR=0.86; 95% CI, 0.70-1.06). 
❚ Additional risk factors for GI bleeds. 
Researchers also looked at patients who had 
additional risk factors for GI bleeds (other 
than the exclusion criteria). For patients 
taking both warfarin and an antiplatelet 
agent/NSAID, PPI co-therapy decreased the 
risk of upper GI bleeding whether or not 
the patients had other bleeding risk factors. 
Again, for patients who had additional bleed-
ing risk factors, but were not taking an anti-
platelet agent or NSAID, PPI therapy showed 
no statistically significant effect.
WHAT’S NEW
PPIs offer benefits, but not 
to patients taking warfarin alone
The statistically significant results in this 
large observational study suggest that PPI co- 
therapy is beneficial in reducing the risk of 
upper GI bleeding in patients taking war-
farin plus an antiplatelet agent/NSAID, but 
that PPI co-therapy provides no benefit to pa-
tients taking warfarin exclusively. 
CAVEATS
Study was good, but it wasn’t  
a randomized controlled trial
This study is observational, and not a ran-
domized control trial (RCT). Therefore, un-
known confounding variables may have 
skewed results. For example, patients could 
have taken over-the-counter medications 
that influenced or obscured results, but were 
not included in the data analysis (misclassifi-
cation bias). 
At best, we can infer a correlation be-
tween PPIs and decreased risk of upper GI 
bleeds. We need RCTs to determine whether 
PPIs cause a lower risk.
❚ Don’t overlook the risk of PPIs. This 
study assessed the ability of PPIs to prevent 
bleeds, but did not address the risks of long-
term PPI therapy. Adverse effects of PPIs 
include an increased risk of pneumonia, 
infection with Clostridium difficile, hip and 
spine fractures, anemia, and possibly chronic 
kidney disease and dementia.9-11 In addition, 
cost-analysis studies of PPI therapy are lim-
ited and inconsistent.12 Therefore, it’s best to 
make decisions regarding PPIs after discuss-
ing other risks and benefits.
❚ What about DOACs? Another consid-
eration is the option to prescribe a direct oral 
anticoagulant (DOAC), such as dabigatran, 
rivaroxaban, or apixaban, instead of warfarin. 
DOACs are at least as effective as warfarin at 
preventing stroke in patients with atrial fibril-
lation and may even be safer.13 Dabigatran 
110 mg causes fewer “major bleeding” events 
than warfarin.13 Rivaroxaban has been shown 
to result in fewer fatal bleeding events than 
warfarin due to fatal intracranial bleeds, al-
though it is associated with more GI bleed-
ding.13 Compared with warfarin, apixaban is 
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associated with fewer GI bleeds and lower 
bleeding rates overall.13 Further research is 
warranted to determine if PPI therapy is ben-
eficial to patients taking DOACs. 
CHALLENGES TO IMPLEMENTATION
It’s still a balancing act
When chronic anticoagulation is necessary, 
physicians and patients must attempt to pre-
vent thrombotic events while minimizing the 
risk of GI bleeds. PPIs may be beneficial in 
preventing upper GI bleeds in patients taking 
dual warfarin and antiplatelet therapy, but 
the long-term consequences of PPI therapy 
should not be ignored.                  JFP
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